Adenosine Receptor A3 - Drugs In Development, 2021

July 2021 | 96 pages | ID: A9D871315AE3EN
Global Markets Direct

Abstracts

Adenosine Receptor A3 - Drugs In Development, 2021

SUMMARY

Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy.

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 1, 4, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Male Health, Oncology, Ophthalmology, Infectious Disease, Musculoskeletal Disorders and Women's Health which include indications Non-Alcoholic Steatohepatitis (NASH), Glaucoma, Hepatocellular Carcinoma, Inflammation, Kidney Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Psoriasis, Rheumatoid Arthritis, Arthritis, Autoimmune Disorders, Chemotherapy Induced Pain, Chronic Inflammation, Chronic Kidney Disease (Chronic Renal Failure), Colon Cancer, Coronavirus Disease 2019 (COVID-19), Diabetic Nephropathy, Erectile Dysfunction, Female Sexual Dysfunction, Inflammatory Pain, Male Sexual Dysfunction, Melanoma, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Ocular Hypertension, Plaque Psoriasis (Psoriasis Vulgaris), Post-Operative Pain, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Prostate Cancer and Ulcerative Colitis.

The latest report Adenosine Receptor A3 - Drugs In Development, 2021, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
• The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
• The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Neumentum Inc
Palo BioFarma SL
Protheragen Inc
Adenosine Receptor A3 (ADORA3) - Drug Profiles
BIO-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPP-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
namodenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTM-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ADORA3 for Autoimmune Disorders, Inflammation, Liver Cancer and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ADORA3 for Chronic Inflammation and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Jul 08, 2021: Can-Fite gears up to initiate pivotal phase III liver cancer study
Jun 16, 2021: Can-Fite receives notice of patent allowance in China for NASH treatment
Jun 02, 2021: Can-Fite to Initiate phase IIb NASH study with its drug candidate Namodenoson
Apr 29, 2021: Can-Fite’s phase III psoriasis study achieves 75% enrollment; top line results expected Q4 2021
Apr 22, 2021: Can-Fite expands its phase II COVID-19 study to Europe
Apr 20, 2021: Can-Fite initiates preclinical studies required by FDA and EMA for the registration of its lead drug candidate Namodenoson
Apr 20, 2021: Can-Fite initiates preclinical studies required by FDA and EMA for the registration of its lead drug candidate piclidenoson
Apr 05, 2021: Can-Fite: Cannabis compound inhibits liver cancer growth in preclinical studies
Mar 19, 2021: Can-Fite BioPharma interview to air on bloomberg television U.S. on the RedChip Money Report
Mar 18, 2021: Can-Fite: Topical administration of CF602 fully recovers erectile dysfunction in diabetic model
Mar 08, 2021: Can-Fite BioPharma enrols first patient to study Covid-19 drug
Feb 22, 2021: New positive data from Can-Fite’s liver cancer phase II clinical study with namodenoson
Feb 01, 2021: Can-Fite announces inhibition of liver fibrosis by cannabis compounds in preclinical studies
Jan 28, 2021: Can-Fite’s NASH indication highlighted in webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH”
Jan 08, 2021: Can-Fite announces publication of Namodenoson liver cancer study in peer reviewed journal—Cancers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by BioIntervene Inc, 2021
Pipeline by Can-Fite BioPharma Ltd, 2021
Pipeline by Future Medicine Co Ltd, 2021
Pipeline by Neumentum Inc, 2021
Pipeline by Palo BioFarma SL, 2021
Pipeline by Protheragen Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021